CN105770913A - Compound meglumine diatrizoate injection and use method thereof - Google Patents
Compound meglumine diatrizoate injection and use method thereof Download PDFInfo
- Publication number
- CN105770913A CN105770913A CN201610176829.6A CN201610176829A CN105770913A CN 105770913 A CN105770913 A CN 105770913A CN 201610176829 A CN201610176829 A CN 201610176829A CN 105770913 A CN105770913 A CN 105770913A
- Authority
- CN
- China
- Prior art keywords
- injection
- meglumni
- diatrizoatis
- composita
- injectio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 35
- 239000007924 injection Substances 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 16
- -1 Compound meglumine diatrizoate Chemical class 0.000 title abstract 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 12
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 claims abstract description 11
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 10
- 239000011630 iodine Substances 0.000 claims abstract description 10
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 6
- 229950005811 sodium amidotrizoate Drugs 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 238000007689 inspection Methods 0.000 claims description 5
- 239000003708 ampul Substances 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 206010020850 Hyperthyroidism Diseases 0.000 abstract description 3
- 208000036981 active tuberculosis Diseases 0.000 abstract description 3
- 230000003908 liver function Effects 0.000 abstract description 3
- 201000008827 tuberculosis Diseases 0.000 abstract description 3
- 206010052098 Iodine allergy Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 abstract 1
- 229960005423 diatrizoate Drugs 0.000 abstract 1
- 230000008085 renal dysfunction Effects 0.000 abstract 1
- 239000008223 sterile water Substances 0.000 abstract 1
- 229960005133 diatrizoate meglumine Drugs 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007459 endoscopic retrograde cholangiopancreatography Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000009608 myelography Methods 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007487 urography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0452—Solutions, e.g. for injection
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compound meglumine diatrizoate injection and a use method thereof. The compound meglumine diatrizoate injection is prepared from 1 part of sodium diatrizoate, 6.6 parts of meglumine diatrizoate and the balance of sterile water, wherein the total amount of the sodium diatrizoate and the meglumine diatrizoate is 90.0-110.0 percent of a labelled amount; preferably, the compound meglumine diatrizoate injection is a colorless to faint yellow clear liquid; 60 percent injection contains 292mg/ml of iodine; 76 percent injection contains 370mg/ml of iodine; the compound meglumine diatrizoate injection further comprises sodium hydroxide for adjusting the pH value to 6.5-8.0. According to the compound megumine diatrizoate injection and the use method thereof, the compound injection is stable in property, is easy to store, can be stored in a shading way at the normal temperature, is easy and convenient to operate, and can be widely applied to various people, except people suffering from iodine allergy, hepatic and renal dysfunction, active tuberculosis, multiple myeloma and hyperthyroidism.
Description
Technical field
The present invention relates to hospital's reagent field, particularly relate to clinical reagent, specifically refer to a kind of Injectio Meglumni Diatrizoatis Composita and using method thereof.
Background technology
Diatrizoate meglumine injection, indication is used for vein and retrograde urography for this contrast medium；Brain, breast, abdomen and limb vessel radiography, phlebography and CT；Can be additionally used in articular irrigation, fistulography, hysterosalpingography, endoscopic retrograde ERCP (ERCP), sialography and other inspections.Diatrizoate meglumine injection should not be used in selective coronary arteriography；Cannot be used for myelography, ventriculography or Cisternography, because it is likely to bring out neurotoxic symptom；And traditional diatrizoate meglumine injection has very big drawback on applicable crowd, and then cannot be carried out PET/CT inspection, cause the state of an illness judge inaccurate or incur loss through delay, bring great inconvenience to patient and doctor's diagnosis and treatment.
Summary of the invention
It is an object of the invention to the shortcoming overcoming above-mentioned prior art, it is provided that a kind of Injectio Meglumni Diatrizoatis Composita that can be widely suitable for patient and using method thereof.
To achieve these goals, the Injectio Meglumni Diatrizoatis Composita of the present invention and using method thereof have following composition:
This Injectio Meglumni Diatrizoatis Composita, it is mainly characterized by, and described Injectio Meglumni Diatrizoatis Composita includes:
Sodium amidotrizoate 1 part；
Cardiografin 6.6 parts；
Surplus is aquesterilisa；
Wherein sodium amidotrizoate and total amount is labelled amount the 90.0%～110.0% of cardiografin.
Preferably, described Injectio Meglumni Diatrizoatis Composita is colourless to faint yellow clear liquid, and wherein the injection amount of iodine of 60% is 292mg/ml, and the injection amount of iodine of 76% is 370mg/ml.
It is highly preferred that the injection that the specification of described Injectio Meglumni Diatrizoatis Composita is 60% is 20ml:12g, the injection of 76% is 20ml:15.2g.
It is further preferred that described injection is placed in 20ml ampoule bottle.
It is further preferred that described Injectio Meglumni Diatrizoatis Composita also includes sodium hydroxide to adjust pH value to 6.5～8.0.
A kind of using method of described Injectio Meglumni Diatrizoatis Composita, it is mainly characterized by, and described using method includes:
(1) configuration solution: before carrying out PET/CT inspection, by 2 specifications are 20ml:15.2g 76% compound injection inject in the container containing 1000ml pure water, proportioning is 3.0%；
(2) before injection FDG medicine, half an hour takes 400ml, and drinks complete by whole dosings before supreme machine check after injectable drug.
Preferably, described configuration solution step is adult's proportioning, and minor configures after calculating in proportion according to age and body weight.
Have employed the Injectio Meglumni Diatrizoatis Composita in this invention and using method thereof, compound injection stable in properties is prone to preserve, room temperature shading is preserved, and easy operation easy to use, the various people except iodine preparation allergy sufferers and hepatic and kidney function obstacle person, active tuberculosis, multiple spinal cord tumor and hyperthyroidism person can be widely applicable for.
Detailed description of the invention
In order to more clearly describe the technology contents of the present invention, conduct further description below in conjunction with specific embodiment.
This Injectio Meglumni Diatrizoatis Composita, described Injectio Meglumni Diatrizoatis Composita includes:
Sodium amidotrizoate 1 part；
Cardiografin 6.6 parts；
Surplus is aquesterilisa；
Wherein containing sodium amidotrizoate (C11H8I3N2NaO4) and cardiografin (C11H9I3N2O4·C7H17NO5) total amount is labelled amount 90.0%～110.0%, described Injectio Meglumni Diatrizoatis Composita is colourless to faint yellow clear liquid, and wherein the injection amount of iodine of 60% is 292mg/ml, and the injection amount of iodine of 76% is 370mg/ml；Preferably, the specification of described Injectio Meglumni Diatrizoatis Composita is the injection of 60% is 20ml:12g, the injection of 76% is 20ml:15.2g, and described injection is placed in 20ml ampoule bottle, and described Injectio Meglumni Diatrizoatis Composita also includes sodium hydroxide to adjust pH value to 6.5～8.0.
A kind of using method of described Injectio Meglumni Diatrizoatis Composita, described using method includes:
(1) configuration solution: before carrying out PET/CT inspection, by 2 specifications are 20ml:15.2g 76% compound injection inject in the container containing 1000ml pure water, proportioning is 3.0%；
(2) before injection FDG medicine, half an hour takes 400ml, and drinks complete by whole dosings before supreme machine check after injectable drug.
Preferably, described configuration solution step is adult's proportioning, and minor configures after calculating in proportion according to age and body weight.
Have employed the Injectio Meglumni Diatrizoatis Composita in this invention and using method thereof, compound injection stable in properties is prone to preserve, room temperature shading is preserved, and easy operation easy to use, the various people except iodine preparation allergy sufferers and hepatic and kidney function obstacle person, active tuberculosis, multiple spinal cord tumor and hyperthyroidism person can be widely applicable for.
In this description, the present invention is described with reference to its specific embodiment.But it is clear that still may be made that various amendment and conversion are without departing from the spirit and scope of the present invention.Therefore, description is regarded in an illustrative, rather than a restrictive.
Claims (7)
1. an Injectio Meglumni Diatrizoatis Composita, it is characterised in that described Injectio Meglumni Diatrizoatis Composita includes:
Sodium amidotrizoate 1 part；
Cardiografin 6.6 parts；
Surplus is aquesterilisa；
Wherein sodium amidotrizoate and total amount is labelled amount the 90.0%～110.0% of cardiografin.
2. Injectio Meglumni Diatrizoatis Composita according to claim 1, it is characterised in that described Injectio Meglumni Diatrizoatis Composita is colourless to faint yellow clear liquid, wherein the injection amount of iodine of 60% is 292mg/ml, and the injection amount of iodine of 76% is 370mg/ml.
3. Injectio Meglumni Diatrizoatis Composita according to claim 2, it is characterised in that the specification of described Injectio Meglumni Diatrizoatis Composita is the injection of 60% is 20ml:12g, and the injection of 76% is 20ml:15.2g.
4. Injectio Meglumni Diatrizoatis Composita according to claim 3, it is characterised in that described injection is placed in 20ml ampoule bottle.
5. Injectio Meglumni Diatrizoatis Composita according to claim 1, it is characterised in that described Injectio Meglumni Diatrizoatis Composita also includes sodium hydroxide to adjust pH value to 6.5～8.0.
6. the using method of the Injectio Meglumni Diatrizoatis Composita according to any one of Claims 1 to 5, it is characterised in that described using method includes:
(1) configuration solution: before carrying out PET/CT inspection, by 2 specifications are 20ml:15.2g 76% compound injection inject in the container containing 1000ml pure water, proportioning is 3.0%；
(2) before injection FDG medicine, half an hour takes 400ml, and drinks complete by whole dosings before supreme machine check after injectable drug.
7. the using method of Injectio Meglumni Diatrizoatis Composita according to claim 6, it is characterised in that described configuration solution step is adult's proportioning, and minor configures after calculating in proportion according to age and body weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610176829.6A CN105770913A (en) | 2016-03-25 | 2016-03-25 | Compound meglumine diatrizoate injection and use method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610176829.6A CN105770913A (en) | 2016-03-25 | 2016-03-25 | Compound meglumine diatrizoate injection and use method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105770913A true CN105770913A (en) | 2016-07-20 |
Family
ID=56391606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610176829.6A Pending CN105770913A (en) | 2016-03-25 | 2016-03-25 | Compound meglumine diatrizoate injection and use method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105770913A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735795A (en) * | 1984-03-30 | 1988-04-05 | E. R. Squibb & Sons, Inc. | Alkylammonium complexes of diatrizoic acid as X-ray contrast agents |
| CN101698105A (en) * | 2009-11-23 | 2010-04-28 | 侯树君 | Gastrointestinal tract contrast medium |
-
2016
- 2016-03-25 CN CN201610176829.6A patent/CN105770913A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735795A (en) * | 1984-03-30 | 1988-04-05 | E. R. Squibb & Sons, Inc. | Alkylammonium complexes of diatrizoic acid as X-ray contrast agents |
| CN101698105A (en) * | 2009-11-23 | 2010-04-28 | 侯树君 | Gastrointestinal tract contrast medium |
Non-Patent Citations (1)
| Title |
|---|
| ANDYALVIN: "复方泛影葡胺注射液说明书", 《HTTPS://WENKU.BAIDU.COM/VIEW/D83C074D852458FB770B56E9.HTML》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Seeliger et al. | Up to 50-fold increase in urine viscosity with iso-osmolar contrast media in the rat | |
| Song et al. | Malposition of peripherally inserted central catheter: experience from 3012 cancer patients | |
| Saljoughian | Intravenous radiocontrast media: a review of allergic reactions | |
| Gordon et al. | Studies in Regional Heparinization: Artificial-Kidney Hemodialysis without Systemic Heparinization—Preliminary Report of a Method Using Simultaneous Infusion of Heparin and Protamine | |
| Lybarger | Hypodermoclysis in the home and long-term care settings | |
| CN105770913A (en) | Compound meglumine diatrizoate injection and use method thereof | |
| Berrens et al. | Rhabdomyolysis after LSD ingestion | |
| Matthews | Adverse Effects of Iodine-derived Intravenous Radiopaque Contrast Media. | |
| Ao et al. | First case in China: Onyx for bronchial artery embolization in treatment of refractory massive hemoptysis in one case | |
| CN102120026A (en) | 21(S) argatroban intravenous injection with alcohol as solubilizer | |
| Le Noel et al. | Rapid infusion pump overestimates delivered flow during rapid vascular filling: a bench study | |
| Sánchez et al. | Portable gamma-camera for the diagnosis of brain death diagnosis | |
| Chan et al. | Carotid jugular arteriovenous fistula: an unusual complication of internal jugular vein catheterization in children | |
| Lindeman | Reactions following blood transfusion by the syringe cannula system | |
| CN102727429B (en) | Pidotimod injection with modified stability, and preparation method thereof | |
| Mahon | Investigations in kidney disease | |
| Hasskarl et al. | Complete caval thrombosis secondary to an implanted venous port–a case study | |
| EP3570805B1 (en) | Plastic containers | |
| Washington et al. | Pharmacology and Drug Administration | |
| JP2012051850A (en) | Anticancer agent solution for transcatheter arterial chemoembolization | |
| Pradhan et al. | lodinated Contrast Media: An Update (To Include Reactions and | |
| for Nursing et al. | IV Therapy Management | |
| Sutherland et al. | Emergency department | |
| Sutherland et al. | Emergency department problems | |
| Ockerblad | Practical application of the creatinin renal function test |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 200233 No. 8, building 406, Guilin Road, Shanghai, Xuhui District Applicant after: Shanghai panorama Medical Imaging Diagnosis Center Co Ltd Address before: 200233 No. 8, building 406, Guilin Road, Shanghai, Xuhui District Applicant before: SHANGHAI SHIZHENG MEDICAL IMAGE DIAGNOSIS CENTER CO., LTD. |
|
| COR | Change of bibliographic data | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160720 |
|
| WD01 | Invention patent application deemed withdrawn after publication |